Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy - Galli, M; Franchi, F; Rollini, F (Eur Heart J Cardiovasc Pharmacother, 2022)